Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05367635 | A Study of SKB315 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 246 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05387928 | A Study of KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05549804 | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05954312 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 290 | Vividion Therapeutics, Inc.INDUSTRY | 3 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06428331 | A Study of SKB518 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06725758 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours(TEADES) | recruiting | Phase 1 / Phase 2 | 315 | Orion Corporation, Orion PharmaINDUSTRY | 6 | May 8, 2026 | clinicaltrials |
| NCT06736327 | A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06826040 | SKB445 for Injection in Solid Tumors | recruiting | Phase 1 | 126 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07087197 | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07380386 | SKB105 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 256 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06555744 | A Study of ZW191 in Participants With Solid Tumors | active not recruiting | Phase 1 | 145 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT06726369 | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06819735 | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors(DOMISOL) | recruiting | Phase 1 / Phase 2 | 125 | Domain Therapeutics Australia Pty LtdINDUSTRY | 3 | May 6, 2026 | clinicaltrials |
| NCT07159828 | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 3 | Axion Bio, IncINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 68 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | not yet recruiting | Phase 1 | 96 | AkesoINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT01375114 | The Effects of Ginseng on Cancer-Related Fatigue | active not recruiting | Phase 1 / Phase 2 | 165 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04457778 | First in Human Study of M6223 | completed | Phase 1 | 58 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05824663 | A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 17 | Harbour BioMed US, Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | recruiting | Phase 1 | 110 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT00900497 | A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers | enrolling by invitation | Phase 1 / Phase 2 | 29 | Dipnarine MaharajOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06349837 | Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors | recruiting | Phase 1 | 24 | Sichuan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07298772 | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07300943 | Study in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 306 | Callio TherapeuticsINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT07561554 | Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02993146 | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05300048 | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | terminated | Phase 1 | 34 | Faeth TherapeuticsINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | active not recruiting | Phase 1 | 95 | Immatics Biotechnologies GmbHINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05378425 | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | active not recruiting | Phase 1 | 90 | Nectin Therapeutics LtdINDUSTRY | 3 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03537690 | FID-007 in Treating Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556276 | Study of CMTS1215 Injection in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 456 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05687682 | Safety of AM-928 Infusion in Advanced Solid Tumors | recruiting | Phase 1 | 38 | AcadeMab Biomedical Inc.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07413328 | HWS116 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 56 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07554196 | A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Huahui HealthINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05430360 | Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors(GT201) | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05729399 | Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2026source: clinicaltrials